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Objectives: We examined the in vitro pharmacodynamics and cellular accumulation of the standard anti-
leishmanial drugs amphotericin B and miltefosine in intracellular Leishmania donovani amastigote–macrophage
drug assays.
Methods: Primary mouse macrophages were infected with L. donovani amastigotes. In time–kill assays infected
macrophages were exposed to at least six different concentrations of serially diluted drugs and the percentage
of infected macrophages was determined after 6, 12, 24, 48, 72 and 120 h of exposure. Cellular drug accumula-
tion was measured following exposure to highly effective drug concentrations for 1, 6, 24, 48 and 72 h. Data
were analysed through a mathematical model, relating drug concentration to the percentage of infected cells
over time. Host cell membrane damage was evaluated through measurement of lactate dehydrogenase
release. The effect of varying the serum and albumin concentrations in medium on the cellular accumulation
levels of miltefosine was measured.
Results: Amphotericin B was more potent than miltefosine (EC50 values of 0.65 and 1.26lM, respectively) and
displayed a wider therapeutic window in vitro. The kinetics of the cellular accumulation of amphotericin B was
concentration- and formulation-dependent. At an extracellular concentration of 10lM miltefosine maximum
cellular drug levels preceded maximum anti-leishmanial kill. Miltefosine induced membrane damage in a con-
centration-, time- and serum-dependent manner. Its cellular accumulation levels increased with decreasing
amounts of protein in assay medium.
Conclusions: We have developed a novel approach to investigate the cellular pharmacology of anti-leishmanial
drugs that serves as a model for the characterization of new drug candidates.
Introduction
The leishmaniases are neglected tropical diseases, caused by
parasites of the genus Leishmania. In the human host, parasites
survive and multiply as intracellular amastigotes in the parasito-
phorous vacuole of primarily tissue-resident macrophages.1
Disease manifestations include cutaneous leishmaniasis, mucocu-
taneous leishmaniasis and visceral leishmaniasis (VL).2,3 Based on
recent estimates the leishmaniases are endemic in at least
98 countries and there are 0.7–1.2 million cutaneous leishmaniasis
and 0.2–0.4 million VL cases each year. The number of deaths
attributed to VL is estimated at 20000–40000 per year.4 There is
currently no vaccine licensed for human use and available drug
treatments have limitations.5,6
Pharmacokinetics/pharmacodynamics (PK/PD) strives to under-
stand the relationship between drug concentrations and biological
effects. Cellular PK is centred on the evaluation of penetration, dis-
tribution, degradation and efflux of drugs in individual cells and
has been widely applied to research on antibiotics.7 In the case of
intracellular infections, cellular PK is an important determinant of
anti-infective drug action as it describes processes and exposure at
the site of infection, previously limited for anti-leishmanial drugs.
Here we determined the in vitro PD and cellular accumulation
of two VL drugs, miltefosine and amphotericin B, as both the
deoxycholate salt (FungizoneV
R
) and liposomal formulation
(AmBisomeV
R
),5,6 in primary mouse macrophages infected with
Leishmania donovani.
VC The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.
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Materials and methods
Reagents and anti-leishmanial drug stocks
RPMI 1640 medium, DMEM, L-glutamine, acetonitrile, DMSO, tolbutamide,
fatty acid-free BSA, Dulbecco’s PBS (DPBS), PBS and penicillin/streptomycin
were purchased from Sigma (UK). Heat-inactivated FBS (hi-FBS), 0.1% (v/v)
formic acid in water (LC-MS grade), methanol (HPLC grade), water (LC-MS
grade), BSA fraction V and LIVE/DEADV
R
stain were purchased from Fisher
Scientific (UK). Flow Cytometry Staining Buffer was purchased from
eBioscience (UK).
Amphotericin B deoxycholate (FungizoneV
R
) was purchased from
University College London Hospitals (UK). A 5.4 mM stock solution was pre-
pared according to the manufacturer’s instructions. Liposomal amphoteri-
cin B (AmBisomeV
R
) was purchased from Gilead (UK) and the powder
reconstituted following the manufacturer’s directions. Miltefosine was
obtained from Paladin Labs Inc. (Montreal, Canada). A 20 mM stock solution
was prepared as described previously.8
Host cells and infection
Bone marrow-derived macrophages (BMDMs) were obtained from femurs
of female BALB/c mice, aged 6–11 weeks, as described previously.8
Briefly, bone cavities were flushed with DMEM plus 10% hi-FBS, 100 U/mL
penicillin and 100 mg/L streptomycin. Cells were pelleted by centrifugation
(1400 rpm, 10 min, 4C) and re-suspended in the above medium plus 20%
L-929 fibroblast culture supernatant (source of macrophage colony-
stimulating factor). The suspension was incubated in Petri dishes at 37C/5%
CO2 for 6 days with the addition of fresh medium after 3–4 days. Following
replacement of medium with ice-cold PBS and incubation on ice, macro-
phages were gently dislodged with a rubber cell scraper and harvested
by centrifugation at 1500 rpm for 10 min at 4C. Macrophages were re-
suspended in RPMI 1640 medium!10% hi-FBS and plated in 16-well cham-
ber slides (Fisher Scientific, UK) at a density of 4%104 macrophages/well (for
PD and cytotoxicity experiments) or in 4-well chamber slides (Fisher
Scientific, UK) at a density of 2.5%105 macrophages/well (for cellular accu-
mulation experiments). After 8 h of incubation at 37C/5% CO2 L. donovani
amastigotes (strain MHOM/ET/67/HU3 or strain MHOM/Sudan/09/SUKA001),
freshly harvested from the spleen of a Rag-1-knockout (B6) mouse [London
School of Hygiene and Tropical Medicine (LSHTM) breeding colony] and re-
suspended in RPMI 1640 medium!10% hi-FBS, were added at a ratio of 10
amastigotes/1 macrophage.
Mouse peritoneal exudate cells (PECs) were harvested from female
BALB/c mice (LSHTM breeding colony) after intraperitoneal injection of
2% soluble starch as described previously8 and plated in RPMI 1640
medium!10% hi-FBS in 16-well chamber slides at 4%104 macrophages/
well. Cultures were incubated overnight at 37C/5% CO2 and infected the
next day as described above.
Host cells were coincubated with amastigotes overnight at 37C/5% CO2
and non-phagocytosed amastigotes washed off the next day, prior to proc-
essing cell cultures for further experiments as described below.
Host cell surface marker analysis
BMDMs and PECs were suspended in a 5% (w/v) solution of BSA fraction V in
Flow Cytometry Staining Buffer at 2%107 cells/mL. The suspension was
incubated on ice for 20 min and then mixed with an equal volume (50lL) of
antibodies, diluted in Flow Cytometry Staining Buffer. This suspension was
incubated for 45 min on ice in the dark prior to addition of 2 mL of ice-cold
PBS and centrifugation at 1000 rpm for 5 min at 4C. The pellet was resus-
pended in 0.1% LIVE/DEADV
R
stain in ice-cold PBS and incubated on ice for
30 min. Cells were washed three times in Flow Cytometry Staining Buffer
and resuspended in 1 mL of Flow Cytometry Staining Buffer, followed by fil-
tration through a 40lm nylon mesh. Cell suspensions were collected in
pre-cooled FACS tubes, protected from light. Cells were acquired on an LSR
II flow cytometer (BD Biosciences, UK) and data analysis performed using
FlowJo analytic software (Treestar, USA). Fluorescence Minus One and iso-
type controls were included. Antibodies and final dilutions used for surface
staining were CD11b-FITC (Miltenyi Biotec; 1:11), antimouse F4/80-PE
(eBioscience; 1:40), antimouse CD64-APC (Biolegend; 1:200) and antimouse
CD11c-BV421 (Biolegend; 1:20). Antibodies and dilutions used as isotype
controls were rat IgG2b K isotype control FITC (eBioscience; 1:100), rat
IgG2a K isotype control PE (eBioscience; 1:40), mouse IgG1j isotype control
APC (Biolegend; 1:200) and Armenian hamster IgG isotype control BV421
(Biolegend; 1:40). Cells were first gated FSC-H versus FSC-A to select singlets
and subsequently FSC-A versus SSC-A to select cells. Singlet cells were gated
for live cells before being measured for their fluorescence from each sample
fluorophore. The percentage of fluorescent cells against non-fluorescent
cells was determined through Fluorescence Minus One controls.
PD and time–kill studies
Infected mouse peritoneal exudate macrophages or BMDMs were exposed
to 3-fold serial drug dilutions in RPMI 1640 medium!10% hi-FBS, over at
least six different concentrations. The highest concentrations used were
30lM for miltefosine and 1lM for amphotericin B. Selected experiments
included an additional concentration of 3lM for the latter. Untreated con-
trols received medium only. Each concentration and control was tested in
quadruplicate. Cultures were exposed to drug dilutions at 37C/5% CO2 for
6, 12, 24, 48, 72 or 120 h. At 72 h medium and drug dilutions were
refreshed. At experimental endpoints slides were fixed with 100% metha-
nol and stained with 10% Giemsa. One hundred macrophages per well
were examined microscopically and the percentage of infected macro-
phages calculated.
A mathematical model relating drug concentration with percentage
infected cells over time was developed. The apparent intracellular concen-
tration (CI) was predicted using a Hill-type model:
CI ¼ Cp t
c
tc þ tc50
(Eqn 1)
where the covariates were Cp, the extracellular concentration, and t, the
time (h), and the estimated parameters were t50, the time to reach 50% of
the maximum penetration, and c, a shape parameter. The fraction of
infected cells at time t [F(t)] was then predicted from the following:
F tð Þ ¼ FB  FB C
k
I
CkI þ ECk50
(Eqn 2)
where FB is the estimated baseline fraction infected, EC50 is the apparent
concentration to reduce the fraction infected by half, and k is a shape (Hill)
parameter. Model fitting was undertaken with NONMEM (version 7.3) and a
logit transformation used to ensure predictions were between 0% and
100%. Inter-experiment variability was estimated on FB, again using a logit
transformation to ensure FB remained between 0 and 1. Improvements in
model fit were assessed by looking for reductions in the objective function
value upon model parameter addition. Final model evaluation used a visual
predictive check whereby 1000 simulations were performed with the 2.5th,
50th and 97.5th percentiles overlaid on the raw data.
Cellular accumulation studies and drug extraction
Miltefosine, FungizoneV
R
or AmBisomeV
R
was added to infected BMDMs at
selected drug concentrations in RPMI 1640 medium, supplemented
with hi-FBS or BSA, in a volume of 1000lL per well. Each concentration
was tested in quadruplicate. Cultures were incubated at 37C/5% CO2
and chamber slides removed from the incubator at set timepoints.
Amphotericin B-treated macrophages were washed three times in 1000lL
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of cold DPBS prior to the addition of 500lL of 0.1% (v/v) formic acid in water
to each well. Miltefosine-treated macrophages were washed with 3% (w/v)
fatty acid-free BSA in PBS9 and cold DPBS prior to the addition of 500lL of
0.1% (v/v) formic acid in water. Macrophages were lysed in 0.1% (v/v) for-
mic acid in water at room temperature for 30 min with vigorous repeat mix-
ing. Lysis was checked by light microscopy. Amphotericin B extraction from
drug-treated cell lysates was performed by mixing 250lL of cell lysate with
250lL of an 84:16 (v/v) mixture of methanol/DMSO containing 200 ng/mL
tolbutamide as internal standard. For extraction of miltefosine 250lL of
drug-treated cell lysate was mixed with 250lL of acetonitrile containing
200 ng/mL tolbutamide as internal standard. After shaking for 10 min at
200 rpm at room temperature, lysate mixtures were centrifuged at
6600 rpm for 15 min at 4C. Supernatants were transferred to 96-well
plates. Supernatants and cell pellets were stored at –80C prior to drug and
protein quantification. The level of infection in L. donovani-infected samples
was determined in untreated controls.
To calculate apparent intracellular concentrations we determined the
cellular volume per mg of protein from the mean diameter of BMDMs
(16.4+0.8lm) and the total protein content per well (35lg). This gave a
factor of 16lL of cell volume per mg of cell protein for BMDMs.
Drug quantification procedure
Drug levels in samples were quantified using reverse phase gradient elution
on an Agilent 1200 HPLC with specific detection for each compound by mul-
tiple reaction monitoring on an Agilent 6410A triple quadrupole mass spec-
trometer (both systems from Agilent, UK). Calibration standards were
prepared by spiking 237.5lL aliquots of untreated cell lysate with 12.5lL
of drug solution at a number of different concentrations. To these were
added 250lL of the appropriate internal standard solution with further
preparation and storage carried out according to the procedure described
in the last section. Blank, blank! internal standard and quality control sam-
ples were included in the analyses.
Determination of protein concentration in cell lysates
Protein concentrations in cell lysates were determined using the PierceTM
BCA Protein Assay Kit (Fisher Scientific, UK), following the manufacturer’s
protocol.
Cytotoxicity assay
L. donovani (strain MHOM/Sudan/09/SUKA001)-infected BMDMs were
exposed to FungizoneV
R
and miltefosine in RPMI 1640 medium!10% hi-FBS
and RPMI 1640 medium with varying percentages of hi-FBS, respectively. At
set timepoints (1, 6, 24, 48 or 72 h), 50lL aliquots of supernatants were trans-
ferred to 96-well plates and the amount of lactate dehydrogenase (LDH)
measured using the CytoTox 96V
R
Non-Radioactive Cytotoxicity Assay (Fisher
Scientific, UK). Untreated infected BMDMs, maximum LDH release controls
and no-cell controls were included. Each condition was tested in quadrupli-
cate. Absorbance was read at 490 nm and the average values of the culture
medium background subtracted from all values of experimental wells.
Percentage cytotoxicity was calculated by the formula 100% experimental
LDH release (OD490)/maximum LDH release (OD490).
Ethics
Experiments involving animals were carried out under licence in accord-
ance with the Animals (Scientific Procedures) Act 1986 (UK Home Office
Project Licences PPL70/6997 and PPL70/8207) following approval by the
Animal Welfare and Ethics Review Board at LSHTM.
Results
Time–kill studies against intracellular L. donovani
amastigotes in primary mouse macrophages
Estimated EC50 values of amphotericin B and miltefosine were
0.65 and 1.26lM, respectively. As the anti-leishmanial activity did
not occur instantaneously, these values must be considered in
relation to the apparent drug penetration time. Time to reach
50% of maximum drug penetration (t50) was 55.72 h for ampho-
tericin B and 100.01 h for miltefosine. Model parameters are sum-
marized in Table 1 and representative plots along with time–kill
curves are shown in Figure 1.
Evidence-based selection of primary macrophages for
cellular drug accumulation studies
Expression of selected cell surface markers was lower and more
heterogeneous in PECs than in BMDMs. In repeat experiments
F4/80 was expressed by 36.1+0.2% of PECs and 79.6+0.7% of
BMDMs, CD11b was expressed by 56.7+0.5% of PECs and
87.1+1.2% of BMDMs, CD11c was expressed by 21.0+1.5% of
PECs and 72.7+0.3% of BMDMs and CD64 was expressed by
6.2+0.4% of PECs and79.4+0.4% of BMDMs (Figure 2). BMDMs
were chosen as host cells in cellular accumulation studies.
Cellular accumulation of amphotericin B in L. donovani-
infected BMDMs over time
Infected BMDMs were exposed to FungizoneV
R
in RPMI 1640
medium!10% hi-FBS at concentrations exerting .90% intracel-
lular parasite kill (Figure 1). The highest increase in cellular drug
concentration was observed between 1 and 6 h (5–6-fold at 3lM
and 1.6–2.6-fold at 1lM in repeat experiments). At 3lM ampho-
tericin B cellular concentrations also increased between 6 and 24 h
(2–3.4-fold), and between 24 and 48 h (1.3–1.6-fold). At 1lM
amphotericin B cellular drug concentrations increased between
6 and 24 h (1.2–1.9-fold), but remained at similar levels between
24 and 48 h (0.9–1.1-fold differences). At an exposure to 0.3lM
amphotericin B, differences in cellular drug concentrations were
Table 1. Non-linear mixed effects model parameter estimates
Outcome Variable Estimate (%RSEa)
Baseline FB 0.65 (3.7)
Apparent intracellular
concentration
t50 amphotericin (h) 55.72 (15.5)
t50 miltefosine (h) 100.01 (40.6)
c amphotericin 2.55 (8)
c miltefosine 2.09 (17.2)
Fraction of
infected cells
EC50 amphotericin (lM) 0.65 (24.4)
EC50 miltefosine (lM) 1.26 (19.1)
k amphotericin 0.78 (6.3)
k miltefosine 1.12 (17.4)
residual error (logit estimate) 0.26 (13)
a%RSE is the relative standard error expressed as a percentage in
relation to the parameter estimates.
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Figure 1. Time–kill curves for amphotericin B and miltefosine. BMDMs were infected with L. donovani (MHOM/Sudan/09/SUKA001) and exposed to
FungizoneV
R
(a and b), AmBisomeV
R
(c and d) or miltefosine (e and f) at indicated drug concentrations (mM). The percentage of infected macrophages
was evaluated at the indicated timepoints. Visual predictive checks, for respective experiments, comparing the percentage of infected cells (black
open circles) with model-simulated 2.5th, 50th and 97.5th percentiles of 1000 simulated datasets are shown (b, d and f). Data are shown for one of
five separate experiments for miltefosine, six separate experiments for FungizoneV
R
and three separate experiments for AmBisomeV
R
.
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1.3–1.8-fold between 1 and 6 h, 1.3–2.2-fold between 6 and 24 h
and 0.7–1.2-fold between 24 and 48 h (Figure 3).
When infected BMDMs were exposed head-to-head to
FungizoneV
R
and AmBisomeV
R
at amphotericin B concentrations of
1lM, maximum cellular drug concentrations were reached within
24 h following incubation with FungizoneV
R
. In contrast, cellular
amphotericin B concentrations increased over the whole period
following incubation with AmBisomeV
R
. Cellular drug concentra-
tions were higher following exposure to FungizoneV
R
compared
with AmBisomeV
R
at all timepoints tested (Figure 4). This difference
was statistically significant at 1, 6 and 24 h in repeat experiments
and at 48 h in one experiment. Tabulated results are provided in
Table S1 (available as Supplementary data at JAC Online).
Cellular accumulation of miltefosine in L. donovani-
infected BMDMs over time
Infected BMDMs were exposed to miltefosine in RPMI 1640
medium!10% hi-FBS at concentrations exerting .90% intracel-
lular parasite kill (Figure 1). At both concentrations, 30 and 10lM,
respectively, the highest increase in cellular drug concentrations
was observed between 1 and 6 h (3.2- and 2.9-fold at 30lM and
3.4- and 3.9-fold at 10lM in repeat experiments), with a further
increase between 6 and 24 h (1.3- and 1.6-fold at 30 and 10lM).
Concentrations remained similar between 24 and 48 h (in repeat
experiments), and 48 and 72 h (in one experiment), with fold dif-
ferences between 0.9 and 1.1 (Figure 5). Tabulated results are pro-
vided in Table S2.
Profiling toxicity of amphotericin B and miltefosine
against L. donovani-infected BMDMs over time
LDH release was measured as an indicator of plasma membrane
damage. For amphotericin B the highest LDH release observed was
11% and 12% after 6 and 72 h of exposure to a concentration of
3lM in medium containing 10% hi-FBS. LDH release in untreated
controls was 7% (Figure 6a). For miltefosine LDH releases of
40%, 25% and 18% were observed after 72 h of exposure to
30 and 10lM and 48 h exposure to 30lM in medium containing
10% hi-FBS. LDH release in all other drug-treated samples and
untreated controls was 10%. Increasing hi-FBS in the assay
medium to a concentration of 20% decreased LDH releases to
24% and 12% after 72 h of exposure to 30 and 10lM miltefosine.
Lowering the concentration of hi-FBS to 5% induced LDH release at
earlier timepoints and increased its magnitude compared with
medium containing 10% and 20% hi-FBS. LDH release in untreated
controls reached a maximum of 20% after 72 h of exposure to
medium with 5% hi-FBS, but was ,10% at all other timepoints
(Figure 6b and c).
Effect of varying hi-FBS and BSA concentrations in
medium on the cellular accumulation of miltefosine
Assay medium was supplemented either with 20%, 10% and
5% hi-FBS, or 0.5%, 0.25% and 0.125% BSA (equivalent albumin
concentrations present in 20%, 10% and 5% hi-FBS) and cellular
drug levels in L. donovani-infected BMDMs measured after 24 h of
exposure to 30 and 10lM miltefosine. Decreased cellular miltefo-
sine levels were observed with increasing protein concentrations in
medium in all experiments (Figure 7).
Effect of varying host cell numbers on the cellular
accumulation of miltefosine
The effect of host cell density on cell-associated drug concentrations
was investigated after 24 h of exposure of infected BMDMs to two
different concentrations of miltefosine in RPMI 1640 medium!10%
hi-FBS. In one experiment a statistically significant higher (P0.01)
cellular concentration was observed when 125000 cells/well were
exposed to 30lM miltefosine compared with 250000 cells/well.
However, this difference was not reproduced in a repeat experiment
and no difference in cellular concentrations between the two plating
densities was observed at an exposure to 10lM miltefosine
(Figure 8).
Discussion
In vitro evaluation of anti-leishmanial drug activity has been lim-
ited to point estimates of the PD effect, through determination of
EC50 and EC90 values at specified timepoints. Recently, time–kill
experiments for standard anti-leishmanial drugs aimed to identify
the minimal exposure time needed to eliminate viable intracellular
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Figure 2. Expression levels of different surface markers on PECs and
BMDMs. Each data point represents the average percentage of gated cell
populations (n"4) for indicated markers in separate experiments in
PECs (a) and BMDMs (b). Standard deviations were 1.5 for PECs and
4.4 for BMDMs and, thus, they are not shown in the plots. The percen-
tages of live cells in repeat experiments were 79.2+4.4% and 79.3+5.3%
in PECs and 85.7+0.8% and 89.8+2.0% in BMDMs.
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amastigotes at selected drug concentrations.10 Here we devel-
oped a PD modelling approach, where apparent drug concentra-
tions have been used to estimate EC50 values. This approach
allowed characterization of drug effects over the whole evaluation
period, with EC50 values indicating higher potency of amphotericin
B over miltefosine. Modelling of in vitro time–kill experiments has
been applied to other anti-infectives, including antibacterials11
and antifungals,12 but is a novel approach for anti-leishmanials. In
PK/PD models, it is well known that homogenate-derived drug con-
centrations rarely relate to meaningful antimicrobial activity con-
centrations, as drugs are rarely evenly distributed between
compartments and subcellular organelles.13 This may explain why
the sigmoidal shape empirically best described the apparent intra-
cellular concentrations, which were based on antimicrobial activity
inferred from a decreasing percentage of infected cells.
Amphotericin B and miltefosine display similar activities against
intracellular L. donovani amastigotes in peritoneal exudate macro-
phages and BMDMs,8 supporting the use of both cell types in PD
studies. However, to provide a rational approach for the selection
of one cell type in drug accumulation studies we characterized
cells obtained from peritoneal exudate and 6 day differentiated
macrophages from bone marrow through their expression of
selected surface markers, including F4/80, CD11b, CD11c and
CD64.14–16 The lower percentage of PECs expressing these markers
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Figure 3. Concentrations of cell-associated amphotericin B over time following exposure to FungizoneV
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Data represented by diamonds and squares were obtained in the same experiment, as well as data represented by triangles and crosses. (a and c)
Data for all drug concentrations. (b and d) Data for the lower two drug concentrations. Data points represent the means (n"4) and the error bars
represent the standard deviations. Data are shown for one of two or three separate experiments.
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Figure 4. Cellular concentrations of amphotericin B over time following
exposure of infected BMDMs to AmBisomeV
R
(A) or FungizoneV
R
(F).
Experiments were carried out in RPMI 1640 medium!10% hi-FBS.
Columns represent the means (n"4) and the error bars represent the
standard deviations. Data are shown for one of two separate experiments.
Statistical significance, defined as P,0.05, was evaluated by one-way
analysis of variance, assuming Gaussian distribution, and Sidak’s multiple
comparisons test (GraphPad Prism 6). NS, non-significant.
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compared with BMDMs may be due to the harvest of PECs 1 day
after the inflammatory stimulus. A change of subsets of immune
cells over time has been reported for PECs, following a thioglyco-
late stimulus, with neutrophils outnumbering macrophages and
lymphocytes 1 day after stimulation.16
Previous studies have characterized amphotericin B uptake into
CHO and J774 cells17,18 and into L. donovani-infected and -unin-
fected differentiated THP-1 cells.19 However, in these studies cells
were exposed to significantly higher amphotericin B concentra-
tions and for shorter periods of time than used to demonstrate
anti-leishmanial efficacy. Here we measured cellular drug accu-
mulation at concentrations and timepoints selected based on
time–kill curves and PD effects. The kinetics of the cellular accumu-
lation of amphotericin B were concentration- and formulation-
dependent. Exposure to FungizoneV
R
at 3lM amphotericin B
resulted in a steeper concentration versus time curve than expo-
sure to 1 and 0.3lM amphotericin B. Dilution of FungizoneV
R
,5lM
leads to the loss of deoxycholate from the mixture and complete
dissociation.17 Free amphotericin B at ,1lM is predominantly
monomeric and its aggregation state affects drug interaction with
membranes.20 Endocytosis has been demonstrated as the route
of internalization of amphotericin B into CHO cells with both rate
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Figure 5. Concentrations of cell-associated miltefosine over time.
Experiments were carried out in RPMI 1640 medium!10% hi-FBS.
Squares represent cell association at an exposure to 30mM miltefosine and
diamonds represent cell association at an exposure to 10mM miltefosine.
Data points represent the means (n"4) and the error bars represent the
standard deviations. Data are shown for one of two separate experiments.
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Figure 6. Cytotoxicity of amphotericin B and miltefosine against
L. donovani-infected BMDMs. Results are expressed as percentage of
total LDH obtained from completely lysed cells. LDH release was meas-
ured after incubation of cells (a) in medium with 10% hi-FBS at amphoteri-
cin B concentrations of 3 and 1mM, (b) in medium with 5%, 10% or 20%
hi-FBS at miltefosine concentrations of 30mM or (c) in medium with 5%,
10% or 20% hi-FBS at miltefosine concentrations of 10mM. Columns repre-
sent the means (n"4) and the error bars represent the standard devia-
tions. Data are shown for one of two separate experiments. Ctl, control.
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and drug distribution along the endocytic pathway concentration-
dependent.18 The lower cellular drug accumulation following incu-
bation with AmBisomeV
R
compared with FungizoneV
R
is consistent
with previous observations17,19 and it is known that the lipids in
AmBisomeV
R
slow the rate of transfer of amphotericin B molecules
to cell membranes.21
Highly effective amphotericin B concentrations caused minimal
membrane damage. In contrast, effective miltefosine concentra-
tions caused LDH release, indicating a narrower in vitro therapeutic
window of miltefosine over amphotericin B. Miltefosine induced
membrane damage in mammalian cells in a concentration-, time-
and serum-dependent manner, possibly through its interaction
with membrane proteins and induction of structural changes.22
A number of studies have investigated cell uptake and membrane
interactions of miltefosine23–25 and an efflux transporter has been
identified in human macrophages.26 In KB cells miltefosine was
located in the plasma membrane and, to a greater extent, intracel-
lular membranes, with a rapid distribution between plasma and
intracellular membranes.25 We noted that, at an extracellular con-
centration of 10lM miltefosine, the timepoint at which maximum
total cellular drug concentrations were reached preceded the
timepoint at which maximum parasite killing was observed. Rapid
drug distribution throughout the cell would rule out drug distribu-
tion as an explanation and support a mode of time-dependent
killing for miltefosine.
Miltefosine binds to plasma proteins from rats, dogs and humans
(www.accessdata.fda.gov, application number 204684Orig1s000),
with albumin identified as the major protein involved in binding in
human serum.27 As hypoalbuminaemia is observed in human and
experimental VL28,29 we investigated the effect of varying albumin
concentrations in assay medium on cellular miltefosine levels and
membrane damage. Although protein binding is species-specific,30
the inverse relationship between serum/albumin concentration in
medium and LDH release suggests that membrane damage is
caused by unbound miltefosine. In addition, the inverse relationship
between the serum/albumin concentration in medium and cellular
drug accumulation supports the model in which unbound miltefo-
sine interacts with plasma membranes of host macrophages and is
the predominant species to be internalized.31 A lower threshold of
cytotoxicity in the absence of serum has previously been reported
for amphotericin B.17 Another feature of human and experimental
VL is the accumulation of mononuclear phagocytic cells in infected
tissues.32,33 In L. donovani-infected spleens in BALB/c mice the
percentage and total number of red pulp macrophages increase by
1.9- and 6.5-fold, respectively, within 35 days of infection.34
However, within the two different host cell densities used here no
clear relationship between host cell number and drug accumulation
emerged.
In conclusion, we have developed a novel approach to investi-
gate in vitro PD and cellular anti-leishmanial drug accumulation
over time and have applied this to investigate how host factors
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Figure 7. Effect of different hi-FBS and BSA concentrations on cell-asso-
ciated miltefosine. Medium was supplemented with 20%, 10% or 5% hi-
FBS (a) or 0.5%, 0.25% or 0.125% of BSA (b) and cells exposed to drug
dilutions for 24 h. Columns represent the mean (n"4) and error bars
standard deviations. Data are shown for one of two separate experi-
ments for each condition.
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Figure 8. Effect of host cell numbers on cell-associated miltefosine.
Columns represent the means (n"8) and the error bars represent the
standard deviations. Data are shown as combined data from two separate
experiments. Statistical significance, defined as P,0.05, was evaluated by
one-way analysis of variance, assuming Gaussian distribution, and Sidak’s
multiple comparisons test (GraphPad Prism 6). NS, non-significant.
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impact on drug accumulation. The work presented here provides a
model for the characterization of new compounds and drug
candidates.
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